1 active not recruiting, 1 completed, 1 recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow Richter Transformation Lymphoma: new trials by email Literature Review of Richter Transformation Lymphoma trials Research Report on Richter Transformation Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies UB-VV400, Rapamycin (sirolimus) - Lymphoma, B Cell, Lymphoma Non-Hodgkin | Phase 1 / Phase 2 | Recruiting | Umoja Biopharma | 274 | 2026-09-01 | 2026-10-09 |
| A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) Zilovertamab vedotin, Nemtabrutinib - Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 2 | Active not recruiting | Merck Sharp & Dohme LLC | 189 | 2022-07-21 | 2026-08-21 |
| A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) Zilovertamab vedotin - Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 1 | Completed | VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 91 | 2019-03-14 | 2024-01-12 |
Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, Follicular (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Mantle-Cell (2) · Lymphoma, Non-Hodgkin (2) · Burkitt Lymphoma (1) · Leukemia (1) · Leukemia, B-Cell (1) · Leukemia, Lymphoid (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, T-Cell (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Chronic Disease (2) · Disease Attributes (2) · Hematologic Diseases (2) · Lymphoma (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Blood Protein Disorders (1) · Cardiovascular Diseases (1)
Sirolimus (1)
Merck Sharp & Dohme LLC (1) · Umoja Biopharma (1) · VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)
United States (3) · Brazil (1) · Canada (1) · Chile (1) · China (1) · Czechia (1) · Estonia (1) · Germany (1) · Ireland (1) · Israel (1) · Italy (1) · Japan (1) · Peru (1) · Poland (1) · Portugal (1)
Luke Walker, MD (1)